Published in Biochem J on July 15, 2007
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem (2008) 3.86
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J (2008) 3.51
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro (2009) 2.85
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J (2010) 2.82
The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem (2008) 2.77
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet (2009) 2.55
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A (2008) 2.36
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci (2009) 2.36
It takes two to tango: regulation of G proteins by dimerization. Nat Rev Mol Cell Biol (2009) 2.34
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J (2009) 2.33
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci (2010) 2.20
A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A (2008) 2.12
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol (2010) 1.88
The role of oxidative stress in Parkinson's disease. J Parkinsons Dis (2013) 1.86
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci (2008) 1.86
Kinase drug discovery--what's next in the field? ACS Chem Biol (2012) 1.84
Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun (2008) 1.71
Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet (2011) 1.68
The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun (2009) 1.67
What causes cell death in Parkinson's disease? Ann Neurol (2008) 1.66
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J (2008) 1.62
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta (2008) 1.55
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet (2011) 1.49
Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol (2011) 1.42
Axon degeneration in Parkinson's disease. Exp Neurol (2012) 1.40
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology (2008) 1.39
The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One (2010) 1.39
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J Neurosci Res (2009) 1.38
Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem (2009) 1.36
LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci (2010) 1.35
The WD40 domain is required for LRRK2 neurotoxicity. PLoS One (2009) 1.32
Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis (2010) 1.31
GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet (2012) 1.29
MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem (2010) 1.28
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One (2012) 1.27
Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum Mol Genet (2009) 1.22
Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem (2011) 1.22
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet (2011) 1.21
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife (2016) 1.20
LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One (2011) 1.19
Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry (2010) 1.17
Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am J Pathol (2012) 1.16
A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol Cell Proteomics (2010) 1.15
LRRK2 secretion in exosomes is regulated by 14-3-3. Hum Mol Genet (2013) 1.15
Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression. Mol Brain (2015) 1.12
The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochem J (2012) 1.11
Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med (2012) 1.10
LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One (2012) 1.10
Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One (2012) 1.09
LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet (2011) 1.08
Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One (2009) 1.07
Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays (2010) 1.06
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? J Neuroinflammation (2014) 1.05
Genetics and genomics of Parkinson's disease. Genome Med (2014) 1.04
RhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular response. Cardiovasc Diabetol (2012) 1.04
Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. ACS Chem Neurosci (2012) 1.04
Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends Pharmacol Sci (2012) 1.04
RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics (2007) 1.03
Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet (2010) 1.03
LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status. Front Mol Neurosci (2014) 1.03
Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Front Mol Neurosci (2014) 1.03
Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J Biol Chem (2010) 1.02
Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat Commun (2014) 1.02
Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PLoS One (2012) 0.99
Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proc Natl Acad Sci U S A (2012) 0.99
The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis (2011) 0.99
The R1441C mutation alters the folding properties of the ROC domain of LRRK2. Biochim Biophys Acta (2009) 0.98
Mitochondrial quality control and neurological disease: an emerging connection. Expert Rev Mol Med (2010) 0.98
Coordinate Regulation of Neurite Outgrowth by LRRK2 and Its Interactor, Rab5. Exp Neurobiol (2010) 0.98
ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2. PLoS One (2010) 0.98
α-synuclein, LRRK2 and their interplay in Parkinson's disease. Future Neurol (2012) 0.97
LRRK2 pathobiology in Parkinson's disease. J Neurochem (2014) 0.97
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord (2010) 0.96
Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. Proc Natl Acad Sci U S A (2013) 0.96
Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export. EMBO J (2014) 0.96
Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS One (2010) 0.96
LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins. Neurodegener Dis (2010) 0.95
Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics (2014) 0.94
LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol (2013) 0.94
LRRK2 in Parkinson's disease: function in cells and neurodegeneration. FEBS J (2009) 0.93
Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Hum Mol Genet (2013) 0.92
Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans. PLoS One (2011) 0.91
Models for LRRK2-Linked Parkinsonism. Parkinsons Dis (2011) 0.91
Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation. PLoS One (2012) 0.91
The impact of genetic research on our understanding of Parkinson's disease. Prog Brain Res (2010) 0.90
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid Redox Signal (2011) 0.90
Short- and long-term effects of LRRK2 on axon and dendrite growth. PLoS One (2013) 0.90
Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front Mol Neurosci (2014) 0.89
Update on the functional biology of Lrrk2. Future Neurol (2008) 0.89
Parkinson's disease and immune system: is the culprit LRRKing in the periphery? J Neuroinflammation (2012) 0.88
LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp Neurol (2014) 0.88
LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25. Exp Mol Med (2013) 0.88
The protein kinase complement of the human genome. Science (2002) 35.36
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol (2002) 8.41
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res (2002) 6.64
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol (1998) 5.15
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron (2006) 4.51
Emerging roles of pseudokinases. Trends Cell Biol (2006) 4.48
Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell (2000) 3.94
Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol (1994) 3.68
Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev (2005) 3.59
LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci (2006) 3.58
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet (2005) 3.49
Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell (1995) 3.36
Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta (2003) 2.62
Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J Biol Chem (1998) 2.09
LRRK2 mutations in Parkinson disease. Neurology (2005) 2.01
A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology (2005) 2.00
Identification of protein phosphorylation sites by a combination of mass spectrometry and solid phase Edman sequencing. J Biomol Tech (2002) 1.97
The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol Biol Evol (2006) 1.94
Regulation of F-actin binding to platelet moesin in vitro by both phosphorylation of threonine 558 and polyphosphatidylinositides. Mol Biol Cell (1999) 1.91
Moesin, ezrin, and p205 are actin-binding proteins associated with neutrophil plasma membranes. Mol Biol Cell (1995) 1.87
A novel cGMP signalling pathway mediating myosin phosphorylation and chemotaxis in Dictyostelium. EMBO J (2002) 1.87
Suppression of radixin and moesin alters growth cone morphology, motility, and process formation in primary cultured neurons. J Cell Biol (1998) 1.63
Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord (2007) 1.56
Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes. EMBO J (2000) 1.47
LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol Med (2006) 1.44
Identification of four candidate cGMP targets in Dictyostelium. Proc Natl Acad Sci U S A (2002) 1.38
Replacement of threonine 558, a critical site of phosphorylation of moesin in vivo, with aspartate activates F-actin binding of moesin. Regulation by conformational change. J Biol Chem (1999) 1.20
KESTREL: a powerful method for identifying the physiological substrates of protein kinases. Biochem J (2006) 1.09
Searching for biomarkers of Aurora-A kinase activity: identification of in vitro substrates through a modified KESTREL approach. J Proteome Res (2005) 1.06
Small is beautiful: what flies tell us about ERM protein function in development. Trends Cell Biol (2004) 0.99
The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J (2004) 10.82
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J (2008) 7.18
The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol (2010) 6.91
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol (2004) 5.10
FAPPs control Golgi-to-cell-surface membrane traffic by binding to ARF and PtdIns(4)P. Nat Cell Biol (2004) 4.85
Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J (2005) 4.82
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J (2008) 4.51
Emerging roles of pseudokinases. Trends Cell Biol (2006) 4.48
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J (2005) 4.31
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J (2009) 4.12
MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J (2003) 3.77
14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J (2004) 3.60
The WNK1 and WNK4 protein kinases that are mutated in Gordon's hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases. Biochem J (2005) 3.52
PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol (2012) 3.42
Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J (2004) 3.39
BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J (2007) 3.11
Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J (2007) 3.08
Activation of the thiazide-sensitive Na+-Cl- cotransporter by the WNK-regulated kinases SPAK and OSR1. J Cell Sci (2008) 3.07
Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J (2010) 2.98
Essential role of PDK1 in regulating cell size and development in mice. EMBO J (2002) 2.93
High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol (2002) 2.92
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J (2010) 2.82
Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs. J Biol Chem (2002) 2.79
In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J (2003) 2.74
A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. EMBO J (2002) 2.72
Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem J (2008) 2.67
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell (2013) 2.64
Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab (2004) 2.61
Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J (2003) 2.47
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med (2010) 2.36
Protein lipid overlay assay. Sci STKE (2002) 2.33
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J (2009) 2.33
The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway. J Cell Sci (2008) 2.31
Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A (2009) 2.30
Identification of in vitro and in vivo phosphorylation sites in the catalytic subunit of the DNA-dependent protein kinase. Biochem J (2002) 2.18
LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett (2003) 2.16
Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J (2003) 2.15
Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science (2009) 2.13
Functional interactions of the SPAK/OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1. Biochem J (2006) 2.12
Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J (2003) 2.11
The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J (2004) 2.11
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J (2011) 2.10
Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J (2008) 2.09
The influence of peripheral iridotomy on the intraocular pressure course in patients with pigmentary glaucoma. J Glaucoma (2005) 2.05
Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab (2005) 2.04
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. Biochem J (2013) 2.03
Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol (2005) 2.00
High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J (2002) 1.93
GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem (2004) 1.91
Kinase drug discovery--what's next in the field? ACS Chem Biol (2012) 1.84
Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome. Biochem J (2002) 1.80
Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1 substrate. FEBS Lett (2005) 1.79
Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. EMBO J (2002) 1.78
Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology (2012) 1.77
Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J (2004) 1.77
Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by Serine 312 phosphorylation. J Biol Chem (2003) 1.75
Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366. Biochem J (2002) 1.74
LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol (2013) 1.73
Bioinformatic and experimental survey of 14-3-3-binding sites. Biochem J (2010) 1.73
Activation of the renal Na+:Cl- cotransporter by angiotensin II is a WNK4-dependent process. Proc Natl Acad Sci U S A (2012) 1.73
Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol (2006) 1.72
MSK1 activity is controlled by multiple phosphorylation sites. Biochem J (2005) 1.72
Regulation of activity and localization of the WNK1 protein kinase by hyperosmotic stress. J Cell Biol (2006) 1.68
Analysis of the LKB1-STRAD-MO25 complex. J Cell Sci (2004) 1.65
Regulation of Akt/PKB Ser473 phosphorylation. Mol Cell (2005) 1.64
Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol (2008) 1.63
Phosphorylation of Slx4 by Mec1 and Tel1 regulates the single-strand annealing mode of DNA repair in budding yeast. Mol Cell Biol (2007) 1.61